Moderna's strong move towards COVID-19 vaccination
17/11/20 -"Against the background of Moderna's recent positive announcement that its vaccine candidate mRNA-1273 generated 94.5% efficacy in a phase III trial, we have abandoned our cautious stance on the ..."
Pages
62
Language
English
Published on
17/11/20
You may also be interested by these reports :
03/12/20
Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of ...
02/12/20
Recently, there has been pertinent share price performance divergence between Novartis and Roche. While, for a long time, Novartis had the upper ...
27/11/20
After being range-bound for the most part of 2019, UCB (Add, Belgium) gained momentum in October 2019 when the company made an acquisition in the ...
26/11/20
Novartis unveiled promising performance targets at its 2020 CMD. Besides striving for healthy top-line growth – driven by diverse innovations, the ...